Selective agonists of beta-adrenergic type 3 receptors (bar3) for the treatment of nephrogenic diabetes insipidus
The invention consists of a method to activate cyclic AMP (cAMP)-mediated intracellular response in renal cells by triggering the beta-3 subtype adrenergic receptor (BAR3).